| PubMed ID |
|
25982339 |
Publish Date |
|
2015 May |
| Journal |
|
Eur J Pediatr |
Species |
|
|
| Disease Type |
|
Acute lymphoblastic leukemia |
Technology |
|
|
| Title |
|
Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. |
| Authors |
|
Kuhlen M, Borkhardt A |
| Affiliation |
|
Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University, Moorenstr. 5, 40225, Duesseldorf, Germany |
| Chromothripsis Definition |
|
Close-by breakpoints: NA
Copy number states: NA
Fragments random joining: NA |
| Abstract |
|
Children diagnosed with cancer are considered for inherited cancer susceptibility testing according to well-established clinical criteria. With increasing efforts to personalize cancer medicine, comprehensive genome analyses will find its way into daily clinical routine in pediatric oncology. Whole genome and exome sequencing unavoidably generates incidental findings. The somatic molecular make-up of a tumor genome may suggest a germline mutation in a cancer susceptibility syndrome. At least two mechanisms are well-known, (a) chromothripsis (Li-Fraumeni syndrome) and (b) a high total number of mutational events which exceeds that of other samples of the same tumor type (defective DNA mismatch repair). Hence, pediatricians are faced with the fact that genetic events within the tumor genome itself can point toward underlying germline cancer susceptibility. Whenever genetic testing including next-generation sequencing (NGS) is initiated, the pediatrician has to inform about the benefits, risks, and alternatives, discuss the possibility of incidental findings and its disclosure, and to obtain informed consent prior to testing. CONCLUSIONS: Genetic testing and translational research in pediatric oncology can incidentally uncover an underlying cancer susceptibility syndrome with implications for the entire family. Pediatricians should therefore increase their awareness of chances and risks that accompany the increasingly wide clinical implementation of NGS platforms. What is Known: The proportion of cancers in children attributable to an underlying genetic syndrome or inherited susceptibility is unclear. Pediatricians consider children diagnosed with cancer for inherited cancer susceptibility according to well-established clinical criteria. What is New: Genetic testing of tumor samples can incidentally uncover an underlying cancer susceptibility syndrome. Findings in tumor genetics can be indicative that the tumor arose on the basis of the child's germline alteration, (a) chromothripsis and (b) a high total number of mutational events which exceeds that of other samples of the same tumor type. |
|
